Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
07/06/20 7:21 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jul 6 2020
Summary ToggleAdverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
- Jun 25 2020
Summary ToggleAdverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing
- Jun 15 2020
Summary ToggleAdverum Biotechnologies Announces Leadership Transition
- Jun 4 2020
Summary ToggleAdverum Biotechnologies to Participate in Goldman Sachs 41st Annual Global Healthcare Conference
There are currently no events to display.